Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Neoplasms 3 Lung Neoplasms 2 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pleural Effusion 1 Pituitary Diseases 1 Pituitary ACTH Hypersecretion 1 Obesity 1 Myasthenia Gravis 1 Motor Activity 1 Lymphoma 1 Kidney Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Cardiotoxicity 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Advanced Solid Tumors 1 Adenocarcinoma of Lung 1 ACTH-Secreting Pituitary Adenoma 1

Interventions

Doxorubicin 17 Echocardiography 14 Cyclophosphamide 9 Trastuzumab 8 Exercise 8 Dexrazoxane 8 Electrocardiography 7 Razoxane 6 Carvedilol 6 Vincristine 4 Radiotherapy 4 Filgrastim 4 Docetaxel 4 Methotrexate 3 Granulocyte Colony-Stimulating Factor 3 Etoposide 3 Cisplatin 3 Atorvastatin 3 salicylhydroxamic acid 2 sacubitril and valsartan sodium hydrate drug combination 2 empagliflozin 2 dapagliflozin 2 Tablets 2 Social Determinants of Health 2 Silymarin 2 Prednisone 2 Paclitaxel 2 Neoadjuvant Therapy 2 Magnetic Resonance Spectroscopy 2 Leucovorin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cardiotoxicity × Biomarkers × Clear all

NCT02605512 2023-11-08

BACCARAT

Institut de Radioprotection et de Surete Nucleaire

Phase NA Completed

Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡